IPOs this week : Nov 2 - 6, 20 (wk 45)

IPOs expected to price

• New Oriental Education (NYSE:EDU) prices its Hong Kong IPO on November 3. 

IPO lockup expirations

• GAN (NASDAQ:GAN) on November 1, 
• Ayala Pharmaceuticals (NASDAQ:AYLA) and China Liberal Education (NASDAQ:CLEU) on November 4.

IPOs this week : June 1 - 5, 20 (wk 23)

IPOs expected to price

• Warner Music Group (WMG) set to price its offering on June 2. The former Warner Bros. property set a range of $23 to $26 for 70M Class A shares, with an implied valuation of $13.3B at the top end. Warner's stable of musicians includes Ed Sheeran and Bruno Mars. 
• Pliant Therapeutics (PLRX) coming to the market with 6M shares in an expected range of $14 to $16. 

IPO quiet period expirations

• GAN (NASDAQ:GAN) on June 1
• Ayala Pharma (NASDAQ:AYLA) on June 2

IPO lockup expirations

• LMP Automotive (NASDAQ:LMPX) on June 2.

Ayala Pharmaceuticals (AYLA) began trading on the Nasdaq on Fri 8 May 2020

Ayala Pharmaceuticals, a Phase 2 biotech developing in-licensed Notch inhibitors for aggressive cancers, raised $55 million by offering 3.7 million shares at $15, the midpoint of the $14 to $16 range.

• Headquarters: Israel / Wilmington, DE
• Founded: 2017
• http://www.ayalapharma.com/

The biotech raised 10% more than expected; it originally filed to offer 3.3 million shares.

Rehovot, Israel-based Ayala was founded to to develop treatments for various cancers:

• Recurrent/Metastatic Adenoid Cystic Carcinoma
• Triple Negative Breast Cancer
• Acute lymphoblastic leukemia
• Desmoid, soft tissue tumors

A brief overview video of adenoid cystic carcinoma.

Management is headed by Chief Executive Officer Roni Mamluk, Ph.D., who has been with the firm since 2017 and was previously CEO at biopharmaceutical firm Chiasma and head of preclinical development of an oncology product at Adnexus Therapeutics.

Ayala Pharmaceuticals (AYLA) sets IPO terms

Ayala Pharmaceuticals (AYLA) has filed an updated preliminary prospectus for its IPO of ~3.3M common shares at $14 - 16 per share.
Underwriters' over-allotment will be up to an additional 500K shares.

The Rehovet, Israel-based biopharmaceutical outfit develops treatments for rare and aggressive cancers by leveraging its bioinformatics platform and next-gen sequencing.

https://www.ayalapharma.com/